Decision analysis is a useful tool for evaluation of such disparate endpoints and associated uncertainties. The approach used is cost-utility analysis. The drug raloxifene may represent a preferred alternative in both cases, contingent on a number of factors. Incremental costs per QALY gained are high for nondominated alternatives.
Results are robust to assessed uncertainties.
This project was funded by a grant from the Institute of Health Economics in Edmonton, Alberta. The views expressed in the paper are those of the authors and not the funding organization.